Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arcturus Therapeutics Holdings Inc ARCT

Healthcare Biotechnology
Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid... see more

Recent & Breaking News (NDAQ:ARCT)

Arcturus Therapeutics Announces Completion of Merger with Alcobra Ltd. and Commences Trading on the Nasdaq Global Market

GlobeNewswire November 16, 2017

Alcobra Announces Third Quarter 2017 Financial Results and Provides Corporate Update

GlobeNewswire November 9, 2017

Arcturus Therapeutics to Host Key Opinion Leader Call on Advances in Delivery of Nucleic Acid Medicines on Tuesday, November 7

GlobeNewswire November 2, 2017

Arcturus Therapeutics and Synthetic Genomics Announce Strategic Alliance to Develop Next-Generation Vaccines and Therapeutics

GlobeNewswire October 31, 2017

Arcturus Therapeutics Announces Presentations at Conferences in November

GlobeNewswire October 26, 2017

Mid-Afternoon Market Update: Crude Oil Down 1.25%; Alcobra Shares Spike Higher

Benzinga.com  October 19, 2017

Mid-Day Market Update: Heritage-Crystal Clean Drops On Weak Q3 Results; Imprimis Pharmaceuticals Shares Surge

Benzinga.com  October 19, 2017

Mid-Morning Market Update: Markets Open Lower; Verizon Sales Beat Estimates

Benzinga.com  October 19, 2017

Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines

GlobeNewswire October 19, 2017

Arcturus Therapeutics, Inc. to Present at the Chardan Gene Therapy Conference

GlobeNewswire October 6, 2017

Alcobra Ltd. and Arcturus Therapeutics, Inc. Agree to Merge

GlobeNewswire September 27, 2017

Alcobra Announces Second Quarter 2017 Financial Results and Provides Corporate Update

GlobeNewswire August 11, 2017

Alcobra Updates on its Review of Strategic Alternatives

GlobeNewswire June 23, 2017

Alcobra Announces Cooperation Agreement with Brosh Group and Board Additions

GlobeNewswire June 12, 2017

Technical Insights on Biotech Stocks -- Soligenix, Sorrento Therapeutics, Alcobra, and Akebia Therapeutics

PR Newswire June 9, 2017

Alcobra Announces First Quarter 2017 Financial Results and Provides Corporate Update

GlobeNewswire May 30, 2017

Alcobra Announces Leadership Update

GlobeNewswire May 15, 2017

Alcobra Provides Update on Cancellation of Extraordinary Meeting Called by Brosh Group

GlobeNewswire May 5, 2017

Alcobra Mails Proxy Materials for Extraordinary General Meeting of Shareholders

GlobeNewswire April 24, 2017

Exodus Capital is Summoning an Extraordinary General Meeting

PR Newswire April 12, 2017